CMPS (COMPASS Pathways) שווי פעילות לרווח לפני ריבית, מסים ופחת
The share price retrospective for COMPASS Pathways plc (CMPS) demonstrates an EV/EBITDA of 0.00. High barriers to entry are driven by costly research and patent protection of chemical compounds, which complicates market access for new players. The business relies on the optimization of cross-border supplies for clinics, while future revenues depend on the agreement of psilocybin-based therapy pricing with government regulators.
פילוחי מדדים מקיפים ואנליטיקה עבור compasspathways.com (CMPS)
COMPASS Pathways plc (CMPS) invests in scientific collaborations with psychopharmacology institutes to develop breakthrough therapies. These expenditures impact operating profit, which the metric compares against the total enterprise value, including debt. This indicator measures the payback period of assets by neutralizing the impact of tax regimes and credit loads. By analyzing the trend of the core EV/EBITDA multiple, an investor determines the real value of COMPASS Pathways plc (CMPS) relative to its ability to generate cash flow.
